Granules May Be Next Private Equity Target

As EIR Obtained For Chantilly, US Facility

A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for private equity funds.

Question mark
Is Granules India Looking For A Buyer? • Source: Shutterstock

The founders of Granules India are said to be in talks with private equity funds like the Blackstone group, KKR & Co, Advent International and Bain Capital to offload part of their 43% shareholding in the publicly-listed company. While the reason or extent of the possible stake sale isn’t immediately clear, a report in the Indian media has cited difficulty in succession planning as a driving factor.

With a valuation of $500m-$550m in mind, the founding Chigurupati family has appointed Kotak Mahindra Capital to look for potential buyers for Granules

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By 

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By 

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.